Precision Chroma Raises $7.3M Seed for Direct Protein Capture

The equipment a bioprocess scientist already knows is part of Precision Chroma's sales argument. The Christchurch biotechnology company is redesigning the structures inside a chromatography column while aiming to preserve the systems, chemistry and operating principles around it. That choice puts the work of adopting a new purification method close to the center of its commercial strategy.

Precision Chroma closed a $7.3M Seed round on October 11, 2026, led by M Ventures, the corporate venture arm of Merck KGaA, Darmstadt, Germany. Founding investor Bridgewest Ventures continued its support, with Icehouse Ventures and Aspire NZ Seed Fund joining the financing. CEO and co-founder Sean Feast will use the capital to advance the company's first research and process-development products, expand manufacturing capacity and develop larger-format columns.

The company wants therapeutic proteins to be captured directly from material leaving a bioreactor, potentially removing clarification operations that typically precede chromatography. Its longer-term development path includes GMP manufacturing applications. For scientists planning purification workflows, the immediate proposition is a different way to prepare and capture a valuable biological product using equipment they can recognize.

Direct capture changes what reaches the column

Precision Chroma's technology addresses the preparation work before protein capture. In the conventional workflow described in its funding announcement, bioreactor harvest passes through centrifugation and depth filtration before Protein A chromatography. Those operations remove cells and debris, but also introduce equipment, consumables and opportunities for product loss. The company is trying to move more of that separation work into the chromatography stage itself.

Precision Chroma uses advanced 3D-printing techniques to build highly ordered agarose packed-bed structures. The macroporous architecture is designed to let cells and debris pass through while therapeutic proteins bind through affinity chemistry. A process scientist would therefore be evaluating both the capture of the desired protein and the passage of everything accompanying it. Successful separation has to account for the whole feed stream, rather than only the molecule the customer wants to keep.

The company's stated design goal is to operate with existing chromatography systems and conventional process conditions. That limits the scope of the equipment change being proposed, while leaving a consequential change in the purification workflow to evaluate. Familiar machinery can help make a new method understandable; the performance of the engineered bed remains application-specific work for the company and its collaborators.

A Canterbury research project becomes a customer product

Precision Chroma's origin predates this financing by years. The University of Canterbury's profile of Sean Feast traces the technology to Professor Conan Fee and describes the development work Feast undertook through his PhD and subsequent research. KiwiNet's institutional account places the company spinout at the beginning of 2022, with Bridgewest Ventures and Callaghan Innovation supporting the commercialization journey.

That history explains why the first commercial audience is important. Researchers and process-development scientists have the practical task of deciding how a purification method fits a particular biological material. Precision Chroma is putting its columns in front of people who can examine that fit, with a product proposition centered on handling unclarified feed. The technical question becomes part of a customer's own process-design work.

The current product page anticipates a sample release of ProA Complete Capture Columns in late 2026. Precision Chroma says those columns are designed to purify antibodies directly from whole mammalian cell culture without prior clarification. The wording describes a prospective release and intended function. Keeping that timing distinct from the longer GMP pathway gives customers a clearer view of the stage of product development the new capital is financing.

An investor who has built a bioprocessing company

M Ventures brings a relevant founder history into the financing. Its Investment Director Oliver Hardick founded bioprocessing tools company Puridify in 2013 and led it through venture funding to acquisition by GE Healthcare in 2017, according to his official biography. His experience connects academic research, a young company's commercial development and the requirements of a larger industrial organization.

In Precision Chroma's announcement, Hardick identifies a gap between upstream bioprocess productivity and downstream purification. He also explicitly recognizes the adoption difficulties associated with new chromatography technologies. Precision Chroma's retention of familiar agarose chemistry, ligands, systems and operating principles is part of the investment rationale he describes. The potential process change arrives with an effort to reduce how much surrounding practice must change with it.

The syndicate also connects continuing institutional support with new capital. Bridgewest Ventures supported Precision Chroma from its launch and remains involved in the Seed financing. Icehouse Ventures and Aspire NZ Seed Fund enter alongside that existing relationship. For the company, the round extends a commercialization effort already underway, with manufacturers and scientific users becoming increasingly important participants in how the product develops.

Manufacturing scale and the order of commercialization

The $7.3M financing supports several connected tasks: scaling Precision Chroma's manufacturing platform, developing larger columns, expanding the team and deepening collaborations with biopharmaceutical manufacturers. Research and process-development products come first in the company announcement, followed by a longer-term path toward GMP manufacturing applications. Each stage has a different customer conversation attached to it.

A researcher can evaluate a separation method against a specific experimental need. A process-development team considers where that method fits within a broader purification sequence. Larger manufacturing applications extend the question to a different format and operating context. Precision Chroma's announced progression gives the company places to develop its architecture while bringing more demanding applications into view. The funding release supplies that direction without providing a completed manufacturing deployment or an approval milestone.

For biopharmaceutical operators, the useful detail is the proposed relationship between the column and the work that precedes it. Changing the bed could change the preparation sequence, the consumables involved and the points where product is handled. Those consequences depend on the application and the performance achieved. Sean Feast's first products will bring the engineered Canterbury structures into scientists' own purification decisions, with antibodies to capture and whole cell cultures to move through the bed.